TW200826981A - Tissue plasminogen activator variant uses - Google Patents
Tissue plasminogen activator variant uses Download PDFInfo
- Publication number
- TW200826981A TW200826981A TW096142107A TW96142107A TW200826981A TW 200826981 A TW200826981 A TW 200826981A TW 096142107 A TW096142107 A TW 096142107A TW 96142107 A TW96142107 A TW 96142107A TW 200826981 A TW200826981 A TW 200826981A
- Authority
- TW
- Taiwan
- Prior art keywords
- catheter
- bfr
- visit
- tenecteplase
- subjects
- Prior art date
Links
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 title description 62
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 title description 61
- 229960000187 tissue plasminogen activator Drugs 0.000 title description 17
- 238000001631 haemodialysis Methods 0.000 claims abstract description 453
- 230000000322 hemodialysis Effects 0.000 claims abstract description 453
- 108010039185 Tenecteplase Proteins 0.000 claims abstract description 150
- 229960000216 tenecteplase Drugs 0.000 claims abstract description 149
- 238000000034 method Methods 0.000 claims abstract description 114
- 230000017531 blood circulation Effects 0.000 claims abstract description 12
- 238000011282 treatment Methods 0.000 claims description 260
- 239000008280 blood Substances 0.000 claims description 68
- 210000004369 blood Anatomy 0.000 claims description 67
- 230000004872 arterial blood pressure Effects 0.000 claims description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 230000002159 abnormal effect Effects 0.000 claims description 29
- 239000000243 solution Substances 0.000 claims description 29
- 241000124008 Mammalia Species 0.000 claims description 26
- 229940088598 enzyme Drugs 0.000 claims description 21
- 108090000790 Enzymes Proteins 0.000 claims description 20
- 102000004190 Enzymes Human genes 0.000 claims description 20
- 238000000502 dialysis Methods 0.000 claims description 19
- 230000000717 retained effect Effects 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 239000008215 water for injection Substances 0.000 claims description 5
- 239000008228 bacteriostatic water for injection Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 229940079593 drug Drugs 0.000 description 167
- 239000003814 drug Substances 0.000 description 167
- 230000002411 adverse Effects 0.000 description 128
- 230000006870 function Effects 0.000 description 82
- 238000005259 measurement Methods 0.000 description 70
- 208000032843 Hemorrhage Diseases 0.000 description 46
- 238000004458 analytical method Methods 0.000 description 46
- 208000034158 bleeding Diseases 0.000 description 39
- 230000000740 bleeding effect Effects 0.000 description 39
- 238000011268 retreatment Methods 0.000 description 38
- 230000008569 process Effects 0.000 description 37
- 238000012216 screening Methods 0.000 description 33
- 238000012360 testing method Methods 0.000 description 33
- 229960003318 alteplase Drugs 0.000 description 31
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 30
- 238000011160 research Methods 0.000 description 28
- 208000024891 symptom Diseases 0.000 description 28
- 239000000902 placebo Substances 0.000 description 27
- 229940068196 placebo Drugs 0.000 description 27
- 206010000891 acute myocardial infarction Diseases 0.000 description 24
- 229920000669 heparin Polymers 0.000 description 24
- 239000000523 sample Substances 0.000 description 23
- 102000009123 Fibrin Human genes 0.000 description 22
- 108010073385 Fibrin Proteins 0.000 description 22
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 22
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 22
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 22
- 230000004064 dysfunction Effects 0.000 description 22
- 229950003499 fibrin Drugs 0.000 description 22
- 238000012552 review Methods 0.000 description 21
- 230000034994 death Effects 0.000 description 20
- 231100000517 death Toxicity 0.000 description 20
- 229960002897 heparin Drugs 0.000 description 20
- 238000011221 initial treatment Methods 0.000 description 20
- 238000002483 medication Methods 0.000 description 20
- 238000002560 therapeutic procedure Methods 0.000 description 20
- 239000000203 mixture Substances 0.000 description 19
- 208000007536 Thrombosis Diseases 0.000 description 18
- 230000005856 abnormality Effects 0.000 description 18
- 230000007717 exclusion Effects 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 239000003527 fibrinolytic agent Substances 0.000 description 17
- 230000008859 change Effects 0.000 description 16
- 201000010099 disease Diseases 0.000 description 16
- 238000002347 injection Methods 0.000 description 16
- 239000007924 injection Substances 0.000 description 16
- 230000000306 recurrent effect Effects 0.000 description 16
- 238000003745 diagnosis Methods 0.000 description 15
- 238000011084 recovery Methods 0.000 description 15
- 230000009467 reduction Effects 0.000 description 15
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 15
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 14
- 229940099983 activase Drugs 0.000 description 14
- 230000002265 prevention Effects 0.000 description 14
- 206010036790 Productive cough Diseases 0.000 description 13
- 238000013461 design Methods 0.000 description 13
- 230000036543 hypotension Effects 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 13
- 238000001802 infusion Methods 0.000 description 13
- 210000003802 sputum Anatomy 0.000 description 13
- 208000024794 sputum Diseases 0.000 description 13
- 229960005080 warfarin Drugs 0.000 description 13
- 208000001953 Hypotension Diseases 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 12
- 239000012530 fluid Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 239000008227 sterile water for injection Substances 0.000 description 11
- 206010047249 Venous thrombosis Diseases 0.000 description 10
- 230000002537 thrombolytic effect Effects 0.000 description 10
- 102000001554 Hemoglobins Human genes 0.000 description 9
- 108010054147 Hemoglobins Proteins 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000002035 prolonged effect Effects 0.000 description 9
- 230000002441 reversible effect Effects 0.000 description 9
- 229960000103 thrombolytic agent Drugs 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 230000001186 cumulative effect Effects 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 230000014759 maintenance of location Effects 0.000 description 8
- 238000007726 management method Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 8
- 230000009885 systemic effect Effects 0.000 description 8
- 208000005189 Embolism Diseases 0.000 description 7
- 206010061876 Obstruction Diseases 0.000 description 7
- 208000010378 Pulmonary Embolism Diseases 0.000 description 7
- 239000004202 carbamide Substances 0.000 description 7
- 230000015271 coagulation Effects 0.000 description 7
- 238000005345 coagulation Methods 0.000 description 7
- 238000009533 lab test Methods 0.000 description 7
- 230000002093 peripheral effect Effects 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- 231100000279 safety data Toxicity 0.000 description 7
- 239000004475 Arginine Substances 0.000 description 6
- 206010051055 Deep vein thrombosis Diseases 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 208000034906 Medical device complication Diseases 0.000 description 6
- 206010040047 Sepsis Diseases 0.000 description 6
- 206010066901 Treatment failure Diseases 0.000 description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
- 235000009697 arginine Nutrition 0.000 description 6
- 210000001367 artery Anatomy 0.000 description 6
- 208000011316 hemodynamic instability Diseases 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 238000013146 percutaneous coronary intervention Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000007619 statistical method Methods 0.000 description 6
- 230000001732 thrombotic effect Effects 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- 108010088842 Fibrinolysin Proteins 0.000 description 5
- 102000001938 Plasminogen Activators Human genes 0.000 description 5
- 108010001014 Plasminogen Activators Proteins 0.000 description 5
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 5
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 5
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 5
- 208000037815 bloodstream infection Diseases 0.000 description 5
- 238000001647 drug administration Methods 0.000 description 5
- 230000000004 hemodynamic effect Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 229940127126 plasminogen activator Drugs 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 5
- 229950008882 polysorbate Drugs 0.000 description 5
- 108010051412 reteplase Proteins 0.000 description 5
- 229960002917 reteplase Drugs 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 229960005356 urokinase Drugs 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- -1 cerebrospinal fluids Substances 0.000 description 4
- 201000001352 cholecystitis Diseases 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000003055 low molecular weight heparin Substances 0.000 description 4
- 229940127215 low-molecular weight heparin Drugs 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 229940012957 plasmin Drugs 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000008223 sterile water Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000011477 surgical intervention Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 238000000959 Cochran–Mantel–Haenszel (CMH) test Methods 0.000 description 3
- 208000032170 Congenital Abnormalities Diseases 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- 108010056764 Eptifibatide Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 102000013566 Plasminogen Human genes 0.000 description 3
- 108010051456 Plasminogen Proteins 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 206010038563 Reocclusion Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000005744 arteriovenous malformation Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000013523 data management Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000003073 embolic effect Effects 0.000 description 3
- 238000013171 endarterectomy Methods 0.000 description 3
- 229960004468 eptifibatide Drugs 0.000 description 3
- GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000009610 hypersensitivity Effects 0.000 description 3
- 239000003978 infusion fluid Substances 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 238000002642 intravenous therapy Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000011272 standard treatment Methods 0.000 description 3
- 230000035488 systolic blood pressure Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000034710 Cerebral arteriovenous malformation Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 206010018852 Haematoma Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010019663 Hepatic failure Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000002263 Intracranial Arteriovenous Malformations Diseases 0.000 description 2
- 201000008450 Intracranial aneurysm Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010061340 Peripheral embolism Diseases 0.000 description 2
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 2
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 230000007488 abnormal function Effects 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000021328 arterial occlusion Diseases 0.000 description 2
- 201000000034 arteriovenous malformations of the brain Diseases 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 238000009640 blood culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000000546 chi-square test Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 229960004969 dalteparin Drugs 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 231100000206 health hazard Toxicity 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 231100000835 liver failure Toxicity 0.000 description 2
- 208000007903 liver failure Diseases 0.000 description 2
- 239000012931 lyophilized formulation Substances 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 2
- 229940020573 plavix Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000010206 sensitivity analysis Methods 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000001321 subclavian vein Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 1
- 206010003547 Asterixis Diseases 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108090000227 Chymases Proteins 0.000 description 1
- 102000003858 Chymases Human genes 0.000 description 1
- LMKYZBGVKHTLTN-NKWVEPMBSA-N D-nopaline Chemical compound NC(=N)NCCC[C@@H](C(O)=O)N[C@@H](C(O)=O)CCC(O)=O LMKYZBGVKHTLTN-NKWVEPMBSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010053172 Fatal outcomes Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101710196208 Fibrinolytic enzyme Proteins 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- 108010031891 KHRR 296-299 AAAA T103N Proteins 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- JPIJQSOTBSSVTP-STHAYSLISA-N L-threonic acid Chemical class OC[C@H](O)[C@@H](O)C(O)=O JPIJQSOTBSSVTP-STHAYSLISA-N 0.000 description 1
- 208000009481 Laryngeal Edema Diseases 0.000 description 1
- 206010023845 Laryngeal oedema Diseases 0.000 description 1
- KNKJPYAZQUFLQK-IHRRRGAJSA-N Lys-His-Arg Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CCCCN)N KNKJPYAZQUFLQK-IHRRRGAJSA-N 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108010051181 TNK-tissue plasminogen activator Proteins 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 108010084094 alanyl-alanyl-alanyl-alanine Proteins 0.000 description 1
- 229950002789 alfimeprase Drugs 0.000 description 1
- 108010088666 alfimeprase Proteins 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940090880 ardeparin Drugs 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 230000005988 arterial dysfunction Effects 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229940107792 certoparin Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 229960003958 clopidogrel bisulfate Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 229940072645 coumadin Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960000610 enoxaparin Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000004023 fresh frozen plasma Substances 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 102000046949 human MSC Human genes 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000011850 initial investigation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000002697 interventional radiology Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 229960000899 nadroparin Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000009972 noncorrosive effect Effects 0.000 description 1
- 230000001453 nonthrombogenic effect Effects 0.000 description 1
- 229960004762 parnaparin Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000003016 pheromone Substances 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000005067 remediation Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229960005496 reviparin Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 229940022036 threonate Drugs 0.000 description 1
- 229960005062 tinzaparin Drugs 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L2300/254—Enzymes, proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
- A61M1/285—Catheters therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M2025/0019—Cleaning catheters or the like, e.g. for reuse of the device, for avoiding replacement
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Materials For Medical Uses (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86475806P | 2006-11-07 | 2006-11-07 | |
| US98348907P | 2007-10-29 | 2007-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200826981A true TW200826981A (en) | 2008-07-01 |
Family
ID=39362326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW096142107A TW200826981A (en) | 2006-11-07 | 2007-11-07 | Tissue plasminogen activator variant uses |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8916148B2 (enExample) |
| EP (1) | EP2086571A2 (enExample) |
| JP (1) | JP5871449B2 (enExample) |
| AR (1) | AR063603A1 (enExample) |
| CA (1) | CA2668347C (enExample) |
| CL (1) | CL2007003211A1 (enExample) |
| PE (2) | PE20120639A1 (enExample) |
| TW (1) | TW200826981A (enExample) |
| UY (1) | UY30693A1 (enExample) |
| WO (1) | WO2008070353A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL371760A1 (en) | 2001-11-26 | 2005-06-27 | Genentech, Inc. | Catheter composition and uses thereof |
| US20070014779A1 (en) * | 2002-11-14 | 2007-01-18 | Genentech, Inc. | Plasminogen activator variant formulations |
| CA2668347C (en) | 2006-11-07 | 2017-06-20 | Genentech, Inc. | Tissue plasminogen activator variant uses |
| MY171723A (en) | 2010-12-23 | 2019-10-24 | Gennova Biopharmaceuticals Ltd | Pharmaceutical compositions of tenecteplase |
| GB201415062D0 (en) * | 2014-08-26 | 2014-10-08 | Aplagon Oy | Therapeutic |
| MX383595B (es) * | 2014-10-21 | 2025-03-14 | Gennova Biopharmaceuticals Ltd | Proceso novedoso de purificacion para el aislamiento y produccion comercial de tnk-tpa recombinante (tenecteplasa) |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI831484A7 (fi) | 1982-05-05 | 1983-11-06 | Genentech Inc | Ihmiskudoksen plasminogeenien aktivaattori. |
| US5000185A (en) | 1986-02-28 | 1991-03-19 | Cardiovascular Imaging Systems, Inc. | Method for intravascular two-dimensional ultrasonography and recanalization |
| US5019096A (en) | 1988-02-11 | 1991-05-28 | Trustees Of Columbia University In The City Of New York | Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same |
| US5270198A (en) | 1988-05-20 | 1993-12-14 | Genentech, Inc. | DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells |
| GB8820945D0 (en) | 1988-09-07 | 1988-10-05 | Smith & Nephew | Medical articles |
| NZ230808A (en) | 1988-10-24 | 1993-04-28 | Squibb & Sons Inc | Pharmaceutical compositions and combinations containing an angiotensin-converting enzyme inhibitor and a thrombolytic agent |
| AU7998091A (en) | 1990-05-17 | 1991-12-10 | Harbor Medical Devices, Inc. | Medical device polymer |
| US5399158A (en) | 1990-05-31 | 1995-03-21 | The United States Of America As Represented By The Secretary Of The Army | Method of lysing thrombi |
| US5363754A (en) | 1991-09-03 | 1994-11-15 | Grainco Queensland Co-Operative Association Limited | Apparatus for preparing animal feedstuff from cotton seed |
| EP0786257B1 (en) | 1992-06-03 | 2003-07-30 | Genentech, Inc. | Tissue plasminogen activator glycosylation variants with improved therapeutic properties |
| US5362754A (en) | 1992-11-12 | 1994-11-08 | Univ. Of Tx Md Anderson Cancer Center | M-EDTA pharmaceutical preparations and uses thereof |
| US5688516A (en) | 1992-11-12 | 1997-11-18 | Board Of Regents, The University Of Texas System | Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices |
| DE69426604T2 (de) | 1993-11-24 | 2001-05-10 | Dupont Pharmaceuticals Co., Wilmington | Isoxazoline und isoxazole derivate als fibrinogen rezeptor antagonisten |
| US5849736A (en) | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
| US5885967A (en) | 1994-03-04 | 1999-03-23 | Eli Lilly And Company | Antithrombotic agents |
| US5509896A (en) | 1994-09-09 | 1996-04-23 | Coraje, Inc. | Enhancement of thrombolysis with external ultrasound |
| US5556380A (en) | 1995-04-05 | 1996-09-17 | Duke University | Method for removing fibrin sheaths from catheters |
| CA2178541C (en) | 1995-06-07 | 2009-11-24 | Neal E. Fearnot | Implantable medical device |
| US5772640A (en) | 1996-01-05 | 1998-06-30 | The Trustees Of Columbia University Of The City Of New York | Triclosan-containing medical devices |
| US5932299A (en) | 1996-04-23 | 1999-08-03 | Katoot; Mohammad W. | Method for modifying the surface of an object |
| US5840733A (en) | 1996-07-01 | 1998-11-24 | Redcell, Canada, Inc. | Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes |
| US5837688A (en) | 1996-11-27 | 1998-11-17 | Gelfand; Mathew I. | Use of thrombolytic reagents for prevention of vascular disease |
| GB9626795D0 (en) | 1996-12-23 | 1997-02-12 | Geistlich Soehne Ag | Combating infection in delivery systems |
| WO1998028326A1 (en) | 1996-12-23 | 1998-07-02 | Biochem Pharma Inc. | Bicyclic thrombin inhibitors |
| US5981826A (en) | 1997-05-05 | 1999-11-09 | Georgia Tech Research Corporation | Poly(vinyl alcohol) cryogel |
| JPH10328293A (ja) | 1997-06-04 | 1998-12-15 | Unitika Ltd | 医療用具及びその製造方法 |
| US6206914B1 (en) | 1998-04-30 | 2001-03-27 | Medtronic, Inc. | Implantable system with drug-eluting cells for on-demand local drug delivery |
| US6166007A (en) | 1998-07-02 | 2000-12-26 | Sodemann; Klaus | Antimicrobial locks comprising taurinamide derivatives and carboxylic acids and/or salts thereof |
| US6174537B1 (en) | 1998-09-25 | 2001-01-16 | Becton, Dickinson And Company | Catheter flush solution and method for its use |
| AU3625500A (en) | 1999-03-11 | 2000-09-28 | Du Pont Pharmaceuticals Company | Synergy between low molecular weight heparin and platelet aggregation inhibitors, providing a combination therapy for the prevention and treatment of various thromboembolic disorders |
| BR0010381A (pt) | 1999-03-11 | 2002-02-05 | Du Pont Pharm Co | Método de tratamento da trombose em um mamìfero, e uso de uma combinação de (i) um inibidor do fator xa, e (ii) um composto selecionado do grupo que consiste em aspirina, tpa, um antagonista gpiib/iiia, heparina de baixo peso molecular e heparina |
| CA2302720C (en) | 1999-03-29 | 2009-07-14 | Ed Geistlich Sohne Ag Fur Chemische Industrie | Anticoagulant/sterilizing compositions and methods |
| US6187768B1 (en) | 1999-06-01 | 2001-02-13 | Becton, Dickinson And Company | Kit for flushing medical devices and method of preparation |
| EP1060747A3 (en) | 1999-06-16 | 2001-12-05 | New York Blood Center, Inc. | Fibrin(ogen) degradation and clot lysis by fibrinolytic metalloproteinase |
| US6592564B2 (en) | 1999-07-23 | 2003-07-15 | Vasca, Inc. | Methods and kits for locking and disinfecting implanted catheters |
| US6350251B1 (en) | 2000-01-18 | 2002-02-26 | Biolink Corporation | Biocidal locks |
| US20010031981A1 (en) | 2000-03-31 | 2001-10-18 | Evans Michael A. | Method and device for locating guidewire and treating chronic total occlusions |
| EP1284780B1 (en) | 2000-05-10 | 2008-05-07 | Ash Access Technology, Inc. | A catheter lock solution including a photo-oxidant |
| WO2002017714A2 (en) | 2000-08-25 | 2002-03-07 | Organ Recovery Systems, Inc. | Methods of thrombolytic organ treatment and repair |
| US20050215978A1 (en) * | 2001-05-25 | 2005-09-29 | Ash Stephen R | Method of enhancing catheter patency using a citrate salt catheter lock solution |
| PL371760A1 (en) | 2001-11-26 | 2005-06-27 | Genentech, Inc. | Catheter composition and uses thereof |
| US20070014779A1 (en) | 2002-11-14 | 2007-01-18 | Genentech, Inc. | Plasminogen activator variant formulations |
| EP1442753B1 (en) * | 2003-02-03 | 2007-02-21 | Polaschegg, Hans-Dietrich, Dr.techn. | Composition for the prevention of indwelling device related infection |
| US7696182B2 (en) * | 2004-11-02 | 2010-04-13 | Nd Partners, Llc | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin |
| US7749529B2 (en) * | 2005-02-08 | 2010-07-06 | Ash Access Technology, Inc. | Catheter lock solution comprising citrate and a paraben |
| CA2668347C (en) | 2006-11-07 | 2017-06-20 | Genentech, Inc. | Tissue plasminogen activator variant uses |
-
2007
- 2007-10-30 CA CA2668347A patent/CA2668347C/en active Active
- 2007-10-30 JP JP2009535417A patent/JP5871449B2/ja active Active
- 2007-10-30 EP EP07871279A patent/EP2086571A2/en not_active Ceased
- 2007-10-30 US US12/447,838 patent/US8916148B2/en active Active
- 2007-10-30 WO PCT/US2007/082933 patent/WO2008070353A2/en not_active Ceased
- 2007-11-06 PE PE2011001779A patent/PE20120639A1/es not_active Application Discontinuation
- 2007-11-06 PE PE2007001525A patent/PE20081488A1/es not_active Application Discontinuation
- 2007-11-07 CL CL200703211A patent/CL2007003211A1/es unknown
- 2007-11-07 TW TW096142107A patent/TW200826981A/zh unknown
- 2007-11-07 AR ARP070104960A patent/AR063603A1/es not_active Application Discontinuation
- 2007-11-07 UY UY30693A patent/UY30693A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008070353A2 (en) | 2008-06-12 |
| PE20120639A1 (es) | 2012-05-26 |
| CA2668347A1 (en) | 2008-06-12 |
| US8916148B2 (en) | 2014-12-23 |
| AR063603A1 (es) | 2009-02-04 |
| JP5871449B2 (ja) | 2016-03-01 |
| WO2008070353A3 (en) | 2008-08-28 |
| PE20081488A1 (es) | 2008-10-30 |
| CA2668347C (en) | 2017-06-20 |
| JP2010509229A (ja) | 2010-03-25 |
| EP2086571A2 (en) | 2009-08-12 |
| US20120270299A1 (en) | 2012-10-25 |
| CL2007003211A1 (es) | 2008-05-30 |
| UY30693A1 (es) | 2008-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bagnall et al. | Continuous infusion of low-dose urokinase in the treatment of central venous catheter thrombosis in infants and children | |
| Jacobs et al. | Recombinant tissue plasminogen activator in the treatment of central venous catheter occlusion in children | |
| Sauermann et al. | Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients | |
| Davis et al. | Activity and dosage of alteplase dilution for clearing occlusions of venous-access devices | |
| TW200826981A (en) | Tissue plasminogen activator variant uses | |
| Blaney et al. | Alteplase for the treatment of central venous catheter occlusion in children: results of a prospective, open-label, single-arm study (The Cathflo Activase Pediatric Study) | |
| US20100330083A1 (en) | Plasminogen activator variant formulations | |
| Hilleman et al. | Efficacy, safety, and cost of thrombolytic agents for the management of dysfunctional hemodialysis catheters: a systematic review | |
| WO2019167048A1 (en) | Extracorporeal device and matrix for removing fibrinolytic proteins from biological fluids, methods and uses thereof | |
| CN100478027C (zh) | 导管组合物及其制备药物的用途 | |
| Tumlin et al. | A phase III, randomized, double-blind, placebo-controlled study of tenecteplase for improvement of hemodialysis catheter function: TROPICS 3 | |
| Timoney et al. | Safe and cost effective use of alteplase for the clearance of occluded central venous access devices | |
| Yamaguchi et al. | Efficacy and safety of endoscopic hemostasis with a self-assembling peptide solution in patients with colonic diverticular bleeding: a multicenter pilot study (with video) | |
| Siegel et al. | Cerebral sinus thrombosis in a trauma patient after recombinant activated factor VII infusion | |
| Mayo | Catheter-related thrombosis | |
| Hamblin et al. | Intrapleural tissue plasminogen activator for the treatment of parapneumonic effusion | |
| US9211317B2 (en) | Method of using prourokinase in facilitated percutaneous coronary intervention in patients with acute myocardial infarction | |
| McCloskey | Catheter-related thrombosis in pediatrics | |
| Abma et al. | Necrotizing fasciitis in a dog | |
| Comerota et al. | Phase 2, randomized, open-label study on catheter-directed thrombolysis with plasmin versus rtPA and placebo in acute peripheral arterial occlusion | |
| Sargent et al. | Octreotide‐induced hyperkalemia | |
| Silverberg et al. | Arteriovenous fistula and prolonged hematuria after renal biopsy: treatment with epsilon aminocaproic acid | |
| Mayo | Current treatment options for catheter-related thrombosis | |
| Zwang et al. | Hemodialysis complications | |
| El‐Shaer et al. | Can trajectory nor‐epinephrine infiltration reduce blood loss during percutaneous nephrolithotomy? A double‐blinded randomized controlled trial |